News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Ipsen Aims To Raise €400 Million In IPO
November 23, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ipsen, the French pharmaceuticals company, yesterday unveiled plans to raise about €400m ($470m) in an initial public offering, which would reduce the stake of the family of founder Henri Beaufour and raise funds for research.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
MORE ON THIS TOPIC
Deals
Roche returns to Hansoh with broad $15B ADC deal
October 19, 2026
·
1 min read
·
Gabrielle Masson
Deals
China tightens grip on biotech platform ownership but foreign licensing deals still okay
October 19, 2026
·
2 min read
·
Annalee Armstrong
Venture capital
Estuary sails into kidney disease space with $103M for gene therapies
October 16, 2026
·
1 min read
·
Annalee Armstrong
IPO
City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
October 16, 2026
·
1 min read
·
Jef Akst
